Home > News > EntreMed Contracts With Elan to Produce Panzem(R) Clinical Material
July 13th, 2004
EntreMed Contracts With Elan to Produce Panzem(R) Clinical Material
EntreMed, Inc. today announced that it has entered into a Clinical Supply Agreement with Elan Drug Delivery, Inc. to reformulate and manufacture EntreMed's Panzem(R) in an oral liquid product format. This supply of reformulated Panzem(R) will support EntreMed's clinical oncology program that is planned to begin in early 2005. Elan is manufacturing the reformulated Panzem(R) using its proprietary NanoCrystal(R) technology that enhances product bioavailability and absorption and produces particles that are fifty times smaller than conventional processes.
Vegetable oil ingredient key to destroying gastric disease bacteria: In mice, therapeutic nanoparticles dampen H. pylori bacteria and inflammation that lead to ulcers and gastric cancer November 25th, 2014
Research reveals how our bodies keep unwelcome visitors out of cell nuclei November 24th, 2014
ASU, IBM move ultrafast, low-cost DNA sequencing technology a step closer to reality November 24th, 2014
An Inside Job: UC-Designed Nanoparticles Infiltrate, Kill Cancer Cells From Within November 24th, 2014